Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
作者:
主题词
动物(Animals);抗肿瘤药(Antineoplastic Agents);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);疾病模型, 动物(Disease Models, Animal);内皮细胞(Endothelial Cells);女(雌)性(Female);人类(Humans);小鼠(Mice);小鼠, SCID(Mice, SCID);肿瘤(Neoplasms);表型(Phenotype);哌啶类(Piperidines);喹唑啉类(Quinazolines);信号传导(Signal Transduction);血管内皮生长因子受体2(Vascular Endothelial Growth Factor Receptor-2);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.3892/ijo.2011.1022
PMID
21537841
发布时间
2022-04-16
- 浏览31
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文